Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Cyclosporine-A enhances choline acetyltransferase immunoreactivity in the septal region of adult rats

Borlongan, C V ; Stahl, C E ; Keep, M F ; Elmer, Eskil LU orcid and Watanabe, S (2000) In Neuroscience Letters 279(2). p.73-76
Abstract
Cyclosporine-A (CsA) is the primary anti-rejection drug used for organ and neural transplantation therapy. In addition to its immunosuppressive action, CsA has been recently shown to exert neuroprotective and neurotrophic effects in the central nervous system when able to cross the blood-brain barrier. Postulated mechanisms for these CsA-induced beneficial effects include the drug's powerful inhibition of the calcium-dependent phosphatase calcineurin (CN) and blockade of the assembly of the mitochondrial permeability transition pore. We report here, for the first time, that adult Wistar rats treated with CsA (10 mg/kg per day, i.p. for 9 days) displayed significantly reduced septal CN expression in combination with enhanced levels of... (More)
Cyclosporine-A (CsA) is the primary anti-rejection drug used for organ and neural transplantation therapy. In addition to its immunosuppressive action, CsA has been recently shown to exert neuroprotective and neurotrophic effects in the central nervous system when able to cross the blood-brain barrier. Postulated mechanisms for these CsA-induced beneficial effects include the drug's powerful inhibition of the calcium-dependent phosphatase calcineurin (CN) and blockade of the assembly of the mitochondrial permeability transition pore. We report here, for the first time, that adult Wistar rats treated with CsA (10 mg/kg per day, i.p. for 9 days) displayed significantly reduced septal CN expression in combination with enhanced levels of septal choline acetyltransferase (ChAT) immunoreactivity as compared to controls. The observed enhancement of septal ChAT immunoreactivity suggests potential therapeutic utility of CsA for brain disorders characterized by alterations of the cholinergic system. (Less)
Please use this url to cite or link to this publication:
author
; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Alzheimer’s disease, Septum, Cholinergic system, Immunosuppression, Neurotrophic effects, Calcineurin, Mitochondrial permeability transition pore
in
Neuroscience Letters
volume
279
issue
2
pages
73 - 76
publisher
Elsevier
external identifiers
  • pmid:10674624
  • scopus:0033977759
ISSN
0304-3940
DOI
10.1016/S0304-3940(99)00962-3
language
English
LU publication?
yes
additional info
The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Laboratory for Experimental Brain Research (013041000)
id
cc8583a0-437e-4095-8a9c-24bf97f3861f (old id 1116821)
date added to LUP
2016-04-01 12:32:18
date last changed
2022-01-27 06:27:30
@article{cc8583a0-437e-4095-8a9c-24bf97f3861f,
  abstract     = {{Cyclosporine-A (CsA) is the primary anti-rejection drug used for organ and neural transplantation therapy. In addition to its immunosuppressive action, CsA has been recently shown to exert neuroprotective and neurotrophic effects in the central nervous system when able to cross the blood-brain barrier. Postulated mechanisms for these CsA-induced beneficial effects include the drug's powerful inhibition of the calcium-dependent phosphatase calcineurin (CN) and blockade of the assembly of the mitochondrial permeability transition pore. We report here, for the first time, that adult Wistar rats treated with CsA (10 mg/kg per day, i.p. for 9 days) displayed significantly reduced septal CN expression in combination with enhanced levels of septal choline acetyltransferase (ChAT) immunoreactivity as compared to controls. The observed enhancement of septal ChAT immunoreactivity suggests potential therapeutic utility of CsA for brain disorders characterized by alterations of the cholinergic system.}},
  author       = {{Borlongan, C V and Stahl, C E and Keep, M F and Elmer, Eskil and Watanabe, S}},
  issn         = {{0304-3940}},
  keywords     = {{Alzheimer’s disease; Septum; Cholinergic system; Immunosuppression; Neurotrophic effects; Calcineurin; Mitochondrial permeability transition pore}},
  language     = {{eng}},
  number       = {{2}},
  pages        = {{73--76}},
  publisher    = {{Elsevier}},
  series       = {{Neuroscience Letters}},
  title        = {{Cyclosporine-A enhances choline acetyltransferase immunoreactivity in the septal region of adult rats}},
  url          = {{http://dx.doi.org/10.1016/S0304-3940(99)00962-3}},
  doi          = {{10.1016/S0304-3940(99)00962-3}},
  volume       = {{279}},
  year         = {{2000}},
}